https://pharmadog.xyz/news/563319 pharmadog en 2026-10-19T11:08:33.000Z Roche signs $400 million upfront deal with China's Hansoh, potential $15 billion partnership https://pharmadog.xyz/news/563343 pharmadog en 2026-10-19T11:02:00.000Z Disc Medicine reports positive Phase 3 results for bitopertin in erythropoietic protoporphyria, setting stage for FDA resubmission https://pharmadog.xyz/news/563344 pharmadog en 2026-10-19T11:01:00.000Z Veradermics reports Phase 3 minoxidil pill boosts hair coverage in men https://pharmadog.xyz/news/563211 pharmadog en 2026-10-19T11:00:36.000Z Disc Medicine's rare sun-sensitivity drug meets all endpoints in Phase 3 trial https://pharmadog.xyz/news/563212 pharmadog en 2026-10-19T11:00:09.000Z TriGemX Bio to go public via SPAC to advance migraine drug candidate https://pharmadog.xyz/news/563213 pharmadog en 2026-10-19T11:00:09.000Z Veradermics' oral minoxidil clears late-stage trial endpoints https://pharmadog.xyz/news/562939 pharmadog en 2026-10-19T09:00:00.000Z Saudi Arabia rolls out biotech partnerships to support its $34.6 billion non‑oil growth plan https://pharmadog.xyz/news/562941 pharmadog en 2026-10-19T09:00:00.000Z Early CDMO engagement: balancing speed with flexibility in CMC planning https://pharmadog.xyz/news/562940 pharmadog en 2026-10-19T09:00:00.000Z Study shows low extractables in single-use components support ADC manufacturing https://pharmadog.xyz/news/562751 pharmadog en 2026-10-19T08:35:00.000Z Gilead’s oral ulcerative colitis drug shows significant remission in Phase 2 trial https://pharmadog.xyz/news/562754 pharmadog en 2026-10-19T08:30:00.000Z Editor shares personal loss and calls for assisted suicide options for severe mental illness https://pharmadog.xyz/news/562756 pharmadog en 2026-10-19T08:30:00.000Z Nonprofit arbitrators under No Surprises Act earning large profits, investigation finds https://pharmadog.xyz/news/562753 pharmadog en 2026-10-19T08:30:00.000Z Alphabet’s Isomorphic Labs draws VC interest as it seeks to turn AI protein modeling into drug discovery engine https://pharmadog.xyz/news/562752 pharmadog en 2026-10-19T08:30:00.000Z Immunology Society Split Over California’s $8.4 B Proposition 38 Funding Measure https://pharmadog.xyz/news/562755 pharmadog en 2026-10-19T08:30:00.000Z Measles resurgence threatens Republican midterm prospects, physicians warn https://pharmadog.xyz/news/562371 pharmadog en 2026-10-19T06:00:32.000Z Nouscom secures $135 million Series D to advance lead cancer vaccine into Phase 2 https://pharmadog.xyz/news/563018 pharmadog en 2026-10-19T05:16:00.000Z AbbVie’s combo of Skyrizi and trosunilimab shows higher remission than Skyrizi alone in phase 2 Crohn’s trial https://pharmadog.xyz/news/562119 pharmadog en 2026-10-19T05:00:00.000Z Sino Biological offers validated cytokines to improve organoid culture and research https://pharmadog.xyz/news/561951 pharmadog en 2026-10-19T04:18:00.000Z Merck/Moderna vaccine and Summit/Akeso bispecific therapy among key highlights at ESMO 2026 https://pharmadog.xyz/news/561952 pharmadog en 2026-10-19T04:02:00.000Z Experts tout amylin as promising, potentially gentler obesity target as new combo therapies near FDA review https://pharmadog.xyz/news/561953 pharmadog en 2026-10-19T04:01:00.000Z Multispecific drug design faces growing complexity as more binding arms increase molecular options https://pharmadog.xyz/news/561299 pharmadog en 2026-10-19T00:54:03.000Z Cambridge biologist David Sabatini awarded $6 million after jury rejects harassment claims